11

Sandostatin (Octreotide) LAR is used for treating acromegaly, carcinoid tumors, and neuroendocrine tumors, among other conditions. Novartis owned EP 2377519, which expired on November 18, 2023. This patent covered specific processes for preparing octreotide acetate microparticles. In EU-5 countries, Teva and Pharmathen have approvals for generic versions of Sandostatin LAR, but only Teva has launched […]